Medivir Q4 2022: Fostrox One Step Closer to Phase IIa - Redeye
Redeye comments on Medivir's fourth quarter report. We expect fostrox's dose escalation study to finish shortly, after which the phase IIa part can commence.
ANNONS
Redeye comments on Medivir's fourth quarter report. We expect fostrox's dose escalation study to finish shortly, after which the phase IIa part can commence.